טוען...

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

BACKGROUND: α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes pri...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Neurol
Main Authors: Berge, Guro, Sando, Sigrid B., Albrektsen, Grethe, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, White, Linda R.
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2016
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5031325/
https://ncbi.nlm.nih.gov/pubmed/27653987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0706-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!